Tempus AI (NASDAQ:TEM) Stock: Insider David Epstein Sells 370 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $74.29, for a total value of $27,487.30. Following the transaction, the director directly owned 30,474 shares in the company, valued at $2,263,913.46. This trade represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 2.8%

TEM stock traded down $2.19 during trading on Wednesday, reaching $75.61. The stock had a trading volume of 5,914,520 shares, compared to its average volume of 6,242,277. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a fifty day moving average price of $71.04 and a 200 day moving average price of $57.17. The company has a market capitalization of $13.64 billion, a P/E ratio of -71.33 and a beta of 3.61. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $89.09.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 48.29%. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.46) earnings per share. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.45 earnings per share for the current year.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported Q3 revenue of $411.5 million, up 23.1% year over year, and earnings of $0.07 per share—above expectations for a loss. The company raised its 2026 revenue outlook to $1.60–$1.605 billion and outlined a $65 million adjusted EBITDA target. Tempus Q3 results
• Positive Sentiment: Management cited oncology demand, expanding data partnerships and reimbursement-related pricing gains as growth drivers, including potential pricing upside in 2027. Q3 earnings call highlights
• Positive Sentiment: Several analysts raised price targets after the results: HC Wainwright to $85, and Robert W. Baird and Cantor Fitzgerald to $92. Needham also said the shares were expected to rise. Analysts boost forecasts
• Positive Sentiment: Tempus shares also benefited from strength in AI stocks at the U.S. market open, adding to the positive earnings-driven momentum. AI stocks rise at market open
• Negative Sentiment: Some coverage cautioned that the stock may be fully valued after a sharp recent run and flagged cash-burn concerns. UBS maintained a Hold rating, citing weaker hereditary testing alongside stronger oncology performance. Valuation concerns
• Negative Sentiment: Analysts have also highlighted potential integration challenges related to Tempus’s proposed Personalis acquisition, which could weigh on execution and future performance. Personalis integration risks

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. boosted its stake in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Tempus AI by 2,965.7% during the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after acquiring an additional 486,493 shares during the period. Eagle Health Investments LP acquired a new position in Tempus AI during the first quarter worth about $11,588,000. Finally, Swiss National Bank grew its holdings in Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock worth $8,298,000 after acquiring an additional 600 shares during the period. 24.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on TEM. Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. UBS Group assumed coverage on Tempus AI in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price on the stock. BTIG Research raised their target price on Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Jefferies Financial Group upgraded shares of Tempus AI from an “underperform” rating to a “hold” rating and upped their price target for the stock from $35.00 to $70.00 in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $79.37.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.